^
    The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens to aid in identifying those patients eligible for treatment with XALKORI®(crizotinib).
    Cancer:
    Non Small Cell Lung Cancer
    Gene:
    ALK (Anaplastic lymphoma kinase)
    Drug:
    Alunbrig (brigatinib), Xalkori (crizotinib)
    Method:
    Fluorescence in situ hybridization (FISH)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    08/26/11
    NSCLC
    ALK
    crizotinib
    FDA
    10/24/12
    NSCLC
    ALK
    crizotinib
    CE
    05/22/20
    NSCLC
    ALK
    brigatinib
    FDA
    Confirmatory trial(s)
    PROFILE 1014
    ,
    NCT01154140
    |
    Future Medicine